About omalizumab
Anti-IgE monoclonal antibody
Used for
- Allergic asthma not controlled with inhaled corticosteroids
- Chronic spontaneous hives that remain troublesome despite antihistamines
- Chronic rhinosinusitis with nasal polyps in adults
- IgE-mediated food allergy to reduce allergic reactions after accidental exposure
Usual adult dose
Asthma: 75–375 mg under the skin every 2 or 4 weeks, based on weight and IgE. Hives: 150 or 300 mg every 4 weeks. Other uses have different dosing.
Usual dose in children
Asthma: for ages 6 years and older, 75–375 mg under the skin every 2 or 4 weeks, based on weight and IgE. Hives: ages 12 and older, 150 or 300 mg every 4 weeks. Food allergy: ages 1 and older, weight- and IgE-based dosing.
Common side effects
- Injection-site reactions
- Headache
- Joint or limb pain
- Upper respiratory infections
Important warnings
- Rare, serious allergic reactions can occur, including after many doses.
- Not for treating sudden asthma attacks or acute allergic reactions.
- Some patients need observation after injections; follow prescribed emergency allergy precautions.
- Worsening asthma or other serious symptoms require prompt medical attention.
Pregnancy
Human pregnancy data are limited. Use only when the expected benefit justifies potential risk; untreated asthma can also harm pregnancy.
Breastfeeding
It is not known whether omalizumab passes into human milk. Discuss benefits and uncertainties with a healthcare professional.
Interactions
- No major drug interactions are established; tell clinicians about all medicines and supplements.
- Do not stop inhaled corticosteroids or other asthma medicines without medical guidance.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.